Dr. Reddy's Laboratories Ltd.

Home
India
Hyderabad
Dr. Reddy's Laboratories Ltd.

We are a global pharmaceutical company committed to providing affordable & innovative medicines. Dr. Reddy’s Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first
Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Dr. Reddy’s does not collect nor does it require you to share any personal data or personal information, towards your access to or participation in the Facebook event organised by it. You are advised to not disclose any personally identifiable or confidential or non-public information on social media; you are personally responsible for any data that you may decide to share or post on any social media including on this page and Dr. Reddy’s owes no duty or obligation or liability to you or to any other person for the same. All participants on this Facebook event are required to behave with courtesy to others and to not post any offensive/objectionable messages or to intrude into any other person’s rights of privacy.

17/09/2025

Acid Peptic Diseases (APD)—conditions caused by excess stomach acid, including gastritis, gastric ulcers, and acid reflux—affect approximately 38% of the Indian population, highlighting their widespread prevalence and the growing need for effective management strategies.

In a multinational clinical trial conducted by Dr. Reddy’s across India, South Africa, and Russia, 99% of patients with Erosive Gastroesophageal Reflux Disease (GERD) in the Tegoprazan treatment arm achieved endoscopic healing by Week 8.
Tegoprazan, approved in 21 countries including South Korea and China, is currently under registration in several others and has successfully completed its Phase III trial in the United States. With this launch, Dr. Reddy’s aims to bridge the gap in treatment options for APDs.

With every launch, we remain committed to serving our patients and stakeholders, striving to be their partner of choice as we progress toward our goal of serving over 1.5 billion patients by 2030.

Click here to read more:https://www.drreddys.com/cms/sites/default/files/2025-09/DRL%20release-%20Tegoprazan-%20final%20version-%2016th%20Sept%202025.pdf

(good health and well-being)

Source: Dr. Reddy’s Press Release (PCAB®️) September 2025

12/09/2025

We have signed a definitive agreement with Johnson & Johnson to acquire the Stugeron®️ portfolio and its locally recognized brands — STUGERON®️ FORTE and STUGERON®️ PLUS — across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. Stugeron®️ is indicated for the treatment of vestibular disturbances and vertigo.

With 1 in 10 people worldwide experiencing vertigo in their lifetime, the estimated global prevalence stands at 0.71%, with women more likely to be affected. Vertigo presents significant challenges for individuals, often disrupting their daily routines. Through this acquisition, we aim to bridge this gap while expanding our footprint in the anti-vertigo space and strengthening our Central Nervous System (CNS) portfolio.

Our Chief Executive Officer, Branded Markets (India and Emerging Markets), M.V. Ramana, said:
“Dr. Reddy’s acquisition of the Stugeron®️ brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio. Backed by our strong market access, we intend to extend the reach of Stugeron®️ and its associated products across 18 key markets in the APAC and EMEA regions, including India and Vietnam. This strategic step aligns with our broader commitment to improving patient access and advancing toward our goal of reaching over 1.5 billion patients by 2030.”

Click here to read more:https://www.drreddys.com/cms/sites/default/files/2025-09/Final%20press%20releaseDRLJNJ.pdf

Data source: ET Healthworld

05/09/2025

We have been certified with Diamond Standard recognition for “Zero Waste to Landfill” by TÜV SÜD South Asia Pvt. Ltd. – with 99.9% of our waste successfully diverted from landfills.
This certification is more than a benchmark. It’s a reflection of our belief in doing what’s right. It’s about choosing responsibility over convenience, and long-term impact over short-term ease.

Through thoughtful reuse, recycling, and recovery practices, we have aligned our operations with global best practices in waste management.

At Dr. Reddy’s, we believe that healthcare and environmental care must go hand in hand.

Kudos to the teams who made this possible and are inspired to keep raising the bar for what sustainable healthcare can look like.

15/08/2025

This , we honour a quiet transformation – a journey that began with scarcity, shaped by visionaries, and carried forward by pioneers across the industry.

From being dependent on imports of medicines to becoming a dependable force for global health, India’s pharma story is one of togetherness, empathy, and unwavering commitment to the larger good – making healthcare accessible, affordable, and available – for all.

Here’s to every scientist, manufacturer, policymaker, and frontline worker who helped India become the Pharmacy of the World!

Here’s to purpose.
Here’s to progress.
Here’s to India.

28/07/2025

Over 250 million people live with viral hepatitis—and many don’t even know it. Awareness is the first step to prevention.

This , we reaffirm our commitment to this year’s theme: —starting with awareness!

23/07/2025

Today we announced our Q1 FY'26 financial results.

For more details click here:
https://shorturl.at/fDqeN

23/07/2025

Today we announced our Q1 FY’26 financial results.

For more details click link in bio.

03/06/2025

Our recent roundtable on Public Health hosted by Dr. Reddy’s, Dr. Reddy’s Institute of Life Sciences, Aurigene Oncology Limited, and Citeline, brought together eminent industry experts to explore key healthcare challenges, ongoing initiatives, and the role of technology in advancing public health. A white paper was released on the outcome of this event capturing the major takeaways. Here are some key conversations from the roundtable.

To read the whitepaper, click link in bio.

31/05/2025

Understanding ni****ne cravings starts with recognising the neurological pathways involved. On , here is a guide to help you understand what ni****ne does to your brain chemistry.

29/05/2025

Commemorating , 127 dedicated employees from Dr. Reddy’s came together to handcraft over 173 reusable sanitary pads during a guided, hands-on workshop. Conducted in collaboration with the Youngistaan Foundation, this initiative underscores our commitment to sustainable, health-driven interventions that empower adolescent girls while reducing environmental impact. These eco-friendly pads will soon be distributed to girls in underprivileged communities across Hyderabad—enabling access to safe menstrual hygiene.

In parallel, a team of our employees volunteered at St. Jude’s Centre, spending heartfelt moments with children courageously battling chronic health conditions. Through our partnership with I Can Volunteer (ICV) we offered emotional support, companionship, and moments of joy to these young warriors—who face daily challenges with immense strength and resilience.

Together, these efforts reflect the spirit of collective action and the deep empathy that drives our people to make a meaningful difference.

28/05/2025

Just a few days to go for , the American Society of Clinical Oncology! We invite you to join our team at the ASCO 2025 in Chicago, Illinois from May 30th to June 3rd. This prestigious event will showcase the experts highlighting latest scientific advancements, featuring renowned oncology healthcare professionals from around the world. Engage with our team to explore potential collaborations in innovation aimed at enhancing current oncology practices and improving patient care. Visit booths #15123 and #16154.

We look forward to seeing you!

21/05/2025

We are committed to developing affordable and innovative pharmaceuticals by investing in cutting-edge science and technology, nurturing talented scientists, and fostering an environment that encourages innovation across all aspects of product development.

In this episode of , we hear from Dr. Subramanian Narayanaswamy, Head of Delivery, Parenteral Injectables – IPDO, as he shares his journey into the world of science and his professional trajectory. He highlights the significance of peptides- Semaglutide and Liraglutide, and discusses our market presence in the treatment of diabetes and obesity.

From the very beginning, our strategy and ex*****on have been bold, venturing into new frontiers of science and technology. Our pioneering spirit and relentless pursuit of excellence have led us to achieve numerous industry firsts.

Our series aims to capture this spirit of bold vision and our deep commitment to science, as expressed through the voices of our scientists. In this series, they share their journeys, insights, and the scientific challenges that continue to inspire them.

Click link in bio to watch full video:

Address

Dr. Reddy's Laboratories Limited (Corporate Office), Door No 8-2-337, Road No 3, Banjara Hills
Hyderabad
500034

Website

https://www.drreddys.com/

Alerts

Be the first to know and let us send you an email when Dr. Reddy's Laboratories Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Hyderabad?

Dr. Reddy's Laboratories Ltd.

17/09/2025

12/09/2025

05/09/2025

15/08/2025

28/07/2025

23/07/2025

23/07/2025

03/06/2025

31/05/2025

29/05/2025

28/05/2025

21/05/2025

Address

Website

Alerts

Shortcuts

Share

Category